Adding a new treatment category can look like a formulary decision. Practices typically consider which dosage forms patients may need, how prescribing will fit into existing workflows, and whether the pharmacy can support the program as it grows. Yet one of the most important quality considerations comes earlier: where the ingredients originate, what they were intended for, and whether they are appropriate for the finished medication.

API sourcing in pharmaceutical compounding came under scrutiny in 2026 when the CDC investigated illnesses linked to compounded glutathione injections. More than 25 people across at least four states became ill, and at least three were hospitalized. The injections had been compounded using glutathione ingredients intended for dietary supplements rather than sterile injectable drug production, raising concerns about contamination, including bacterial endotoxins.

For providers evaluating a new compounded medication category, the lesson extends beyond glutathione. An ingredient’s identity alone cannot establish its suitability for human drug compounding. Its source, intended use, documentation, and appropriateness for the route of administration all need to be considered before compounding begins.

Key Takeaways

• An active pharmaceutical ingredient should be evaluated not only by what it is, but also by its source, intended use, documentation, applicable standards, and suitability for the intended route of administration.
• Ingredients intended for dietary supplements, cosmetics, veterinary products, or research use are not automatically interchangeable with materials appropriate for human drug compounding.
• Route matters. An ingredient used in an oral product cannot be assumed appropriate for a sterile injectable preparation simply because the chemical name is the same.
• A certificate of analysis is important, but it is one part of a larger sourcing and qualification process that should also include manufacturer information, lot traceability, applicable specifications, and intended-use information.
• As practices add treatment categories and patient volume grows, ingredient sourcing becomes increasingly important in evaluating whether a compounding pharmacy can support that growth responsibly.
• At Evoluciona Pharma, we use APIs sourced for human pharmaceutical compounding that meet applicable requirements and are appropriate for the intended route of administration. We do not use APIs or ingredients intended solely for dietary supplement, cosmetic, veterinary, or research use in our compounded medications.

Not All Ingredients With the Same Name Are Intended for the Same Use

Two ingredients may share the same chemical identity yet differ considerably in how they were manufactured, tested, handled, and documented. A material intended for dietary supplements, cosmetics, veterinary products, or laboratory research may meet the specifications established for that market without meeting the requirements for human pharmaceutical compounding. Specifications for identity testing, assay, purity, and contaminant limits can differ, affecting whether a material is suitable for its intended pharmaceutical use.

These differences are not always apparent from supplier descriptions. Terms such as high purity or laboratory-tested may accurately describe certain characteristics of an ingredient without establishing its suitability for pharmaceutical compounding. For practices expanding into new medication categories, a pharmacy’s evaluation of the material against applicable compounding requirements is more informative than the supplier’s claims alone.

Route of Administration Changes the Sourcing Question

An ingredient that may be appropriate for one type of product is not necessarily appropriate for another. Oral administration, topical application, and injection expose patients to substances in fundamentally different ways. Injectable medications present particular quality considerations because they bypass many of the body’s natural barriers to contaminants.

Endotoxins are a good example. They are substances associated with certain bacteria and can remain a concern even when viable bacteria are no longer present. Excessive endotoxin exposure through an injectable product can cause reactions ranging from fever and chills to hypotension and severe systemic illness.

An ingredient used in a dietary supplement cannot simply be carried over into sterile compounding on the assumption that finished-product testing will resolve the difference. Following the glutathione investigation, the CDC advised compounding pharmacies to confirm that ingredients used in injectables are manufactured under conditions and specifications appropriate for the intended route of administration. This assessment begins with the material itself, before it enters the compounding process.

What Should Providers Look for Behind an API?

Providers do not need to become supply-chain auditors to ask informed questions about ingredient sourcing. But when a pharmacy relationship supports patient care across a growing number of categories, several pieces of information are worth knowing.

1. Source and manufacturer identity. Supply-chain transparency should let you identify where a bulk drug substance originated, not just the distributor or repackager that supplied it to the pharmacy.
2. Intended use. Documentation should reflect the material’s use in human drug compounding rather than identifying it solely for another market, such as dietary supplements, cosmetics, veterinary products, or laboratory research.
3. Applicable compounding requirements and standards. Under Section 503A, bulk drug substances used in compounding are subject to specific conditions involving applicable USP or National Formulary monographs, components of FDA-approved drugs, or the 503A bulk drug substances framework, depending on the substance. Bulk drug substances must also be accompanied by a valid certificate of analysis and manufactured by an establishment registered with the FDA.
4. Certificate of analysis, or COA. A COA provides lot-specific information about the material and the testing performed. Depending on the ingredient and its specifications, that documentation may address factors such as identity, assay, purity, microbial limits, or bacterial endotoxins.

A COA should not be treated as a stand-alone guarantee of suitability. Even when an ingredient meets its stated testing specifications, those specifications may not be appropriate for its intended pharmaceutical use or route of administration. This is why the FDA emphasizes supplier qualification and ingredient suitability alongside testing. Evaluating a COA alongside the material’s source, manufacturing standards, and intended use provides a more complete picture of API quality.

Why Ingredient Sourcing Becomes More Important as Programs Grow

As a practice expands its compounded medication offerings, the pharmacy relationship becomes more complex. Additional treatment categories, dosage forms, and patient volume may involve new APIs, multiple suppliers, and different manufacturing and testing requirements. Managing these variables requires established processes for supplier qualification, ingredient documentation, and quality oversight.

For practices, much of this work happens behind the scenes, but its importance becomes clearer as programs expand. A pharmacy may be able to compound a broad range of preparations, but supporting those offerings consistently also depends on how it manages ingredient sourcing, supplier changes, lot traceability, and applicable quality requirements. These processes help maintain continuity as formulations and operational demands evolve.

When evaluating a pharmacy partner for a new treatment category, practices can gain useful insight by asking how APIs are sourced and qualified, how supplier changes are managed, and what documentation supports ingredient suitability. The answers offer a clearer picture of the pharmacy’s ability to support an expanding formulary while maintaining appropriate quality standards.

How Evoluciona Approaches API Sourcing

At Evoluciona Pharma, ingredient quality is integral to our compounding process. We source APIs for pharmaceutical compounding, following applicable requirements for human drug compounding and considering their suitability for the intended route of administration. We do not use APIs or ingredients intended solely for dietary supplement, cosmetic, veterinary, or research use in our compounded sterile or nonsterile medications.

Our sourcing procedures include reviewing ingredient documentation, manufacturer information, and lot-level records to support traceability and quality evaluation. These measures work alongside our documented compounding procedures, environmental controls for sterile preparations, and batch-level quality processes to support consistent standards throughout production.

As your practice considers adding new treatment categories, the pharmacy’s approach to ingredient sourcing deserves the same attention as its compounding capabilities and operational support. Knowing how APIs are selected, qualified, and documented can help you assess whether a pharmacy partner is equipped to support your expanding formulary.

Contact us today to learn more about Evoluciona Pharma’s ingredient sourcing, quality processes, compounding capabilities, and provider support.

Frequently Asked Questions

What is an API in pharmaceutical compounding?

An active pharmaceutical ingredient, or API, is the substance in a medication responsible for its intended pharmacologic activity. In compounding, API quality involves more than confirming the ingredient’s identity. Its source, intended use, applicable standards, documentation, and suitability for the preparation and route of administration are also important.

Why does API sourcing matter in a compounding pharmacy?

API sourcing helps determine whether the material entering the compounding process is appropriate for use in a human drug. Providers evaluating a compounding pharmacy may want to know who manufactured the API, what the material was intended for, whether it meets applicable compounding requirements, what documentation accompanies it, and whether it is suitable for the intended route of administration.

Can an ingredient used in a dietary supplement also be used in an injectable compounded medication?

The same active substance may appear in products intended for different routes of administration, but the material used in a sterile injectable must be appropriate for that purpose. FDA and CDC warn against using dietary supplement-grade ingredients to compound sterile injectable drugs because they may contain contaminants or impurities that pose risks when injected.

What information should be included in an API certificate of analysis?

A certificate of analysis (COA) provides lot-specific information about an ingredient and the results of testing against established specifications. Depending on the material, it may include identity, assay, purity, microbial limits, and endotoxin testing results. While a valid COA is an important part of API documentation, it does not independently establish suitability for pharmaceutical compounding. The pharmacy must also consider supplier qualification, manufacturer information, applicable standards, traceability, and whether the ingredient is appropriate for its intended use and route of administration.

Does Evoluciona Pharma use dietary supplement-grade ingredients in compounded injectable medications?

No. Evoluciona Pharma does not use APIs or ingredients intended solely for dietary supplement, cosmetic, veterinary, or research use in its compounded sterile and non-sterile medications. Evoluciona Pharma sources APIs for compounded injectables for pharmaceutical compounding and evaluates them for appropriateness for the intended route of administration.